Herpes Zoster Market - Top Companies and Manufacturers

Companies Dominating the Herpes Zoster Landscape

Besides developing new techniques and medications, global leaders are taking initiatives to grow public awareness about the available solutions, expanding the reach of the herpes zoster market worldwide. The widespread popularity of antiviral drugs is further captivating the focus of pharma giants, willing to solidify their global dominance. This is bringing innovations in this sector, marking steady and potential growth. For instance, in September 2024, GSK partnered with Brooke Shields to spread education about risk and vaccination for shingles by encouraging people aged 50 years or over. As a part of the THRIVE@50+ campaign, the partners aim to promote the effectiveness and importance of available treatments in aging. Such key players include:

GlaxoSmithKline plc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Astellas Pharma Inc.
Foamix Pharmaceuticals
GeneOne Life Science
Merck & Co.
NAL Pharma
Novartis AG
Hoffmann-La Roche Ltd
TSRL Inc.
Pfizer Inc.

Browse Key Market Insights with Data Illustration:

Herpes Zoster Market Size & Share, Growth Trends 2037

In the News

In April 2024, GlaxoSmithKline plc announced the positive results of the long-term follow-up phase III trial of ZOSTER-049, highlighting its 82.0% effectiveness even after 11 years of vaccination with Shingrix. The data further revealed 79.7% efficacy against shingles in adults over 50 and over during the same timeline.
In February 2023, Pfizer Inc. collaborated with BioNTech SE to initiate a Phase 1/2 trial on the safety, tolerability, and immunogenicity of mRNA vaccine candidates against shingles. The multicenter, randomized, controlled, and dose-selection study aims to evaluate and explore the potential of mRNA technology.

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of the herpes zoster market was over USD 400 million.

The market size for the herpes zoster market is projected to reach USD 743.3 million by the end of 2037 expanding at a CAGR of 5.3% during the forecast period i.e., between 2025-2037.

The major players in the market are GlaxoSmithKline plc, Astellas Pharma Inc., Foamix Pharmaceuticals, GeneOne Life Science, Merck & Co., NAL Pharma, Novartis AG, Hoffmann-La Roche Ltd, TSRL Inc., and others.

In terms of route of administration, the oral segment is anticipated to garner the largest market share of 83.1% by 2037 and display lucrative growth opportunities during 2025-2037.

The market in North America is projected to hold the largest market share of 55.4% by the end of 2037 and provide more business opportunities in the future.

Herpes Zoster Market - Top Companies and Manufacturers

Companies Dominating the Herpes Zoster Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the herpes zoster market?

What is the outlook for the herpes zoster market?

Who are the major players dominating the herpes zoster market?

Which route of administration segment will capture the significant market share for the herpes zoster market by 2037?

Which region will provide more business opportunities for the growth of the herpes zoster market in the future?